Canaccord Adams initiates coverage on Protalix BioTherapeutics (NYSE: PLX) with a Buy rating and $11 price target, saying shares have ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE